Cargando…
Results of the observational prospective RealFLOT study
BACKGROUND: Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) has recently become the gold standard treatment for fit patients with operable gastric (GC) or gastroesophageal (GEJ) adenocarcinoma, getting a 5-year overall survival (OS) of 45%, over 23% with surgery alone. METHODS: RealFL...
Autores principales: | Giommoni, Elisa, Lavacchi, Daniele, Tirino, Giuseppe, Fornaro, Lorenzo, Iachetta, Francesco, Pozzo, Carmelo, Satolli, Maria Antonietta, Spallanzani, Andrea, Puzzoni, Marco, Stragliotto, Silvia, Sisani, Michele, Formica, Vincenzo, Giovanardi, Filippo, Strippoli, Antonia, Prisciandaro, Michele, Di Donato, Samantha, Pompella, Luca, Pecora, Irene, Romagnani, Alessandra, Fancelli, Sara, Brugia, Marco, Pillozzi, Serena, De Vita, Ferdinando, Antonuzzo, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499559/ https://www.ncbi.nlm.nih.gov/pubmed/34625033 http://dx.doi.org/10.1186/s12885-021-08768-7 |
Ejemplares similares
-
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study
por: Nappo, Floriana, et al.
Publicado: (2023) -
Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience
por: Lavacchi, Daniele, et al.
Publicado: (2021) -
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing
por: Lavacchi, Daniele, et al.
Publicado: (2023) -
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
por: Lavacchi, Daniele, et al.
Publicado: (2023) -
Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives
por: Fancelli, Sara, et al.
Publicado: (2021)